Market Overview

Aegis Capital Initiates Coverage Recro Pharma with Buy Rating, $40 Price Target

Share:

Latest Ratings for REPH

DateFirmActionFromTo
Dec 2016PiperJaffrayInitiates Coverage OnOverweight
Oct 2016Brean CapitalAssumesBuy
Sep 2016Roth CapitalInitiates Coverage onBuy

View More Analyst Ratings for REPH
View the Latest Analyst Ratings

Posted-In: News Analyst Ratings

 

Related Articles (REPH)